XML 43 R31.htm IDEA: XBRL DOCUMENT v3.3.1.900
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)
 12 Months Ended
Dec. 31, 2015
USD ($)
Institution
License
Plan
$ / shares
shares
Dec. 31, 2014
USD ($)
$ / shares
shares
Cash and Cash Equivalents [Abstract]    
Highly liquid investments $ 0 $ 0
Number of financial institutions deposits are primarily maintained | Institution 2  
Allowance for doubtful accounts receivable $ 0 0
Goodwill [Abstract]    
Goodwill 32,466,000 0
Other Income [Abstract]    
Miscellaneous income $ 4,026,000 45,000
Number of years subject to statute of limitations by major tax jurisdiction 3 years  
Basic and diluted net loss per share [Abstract]    
Net loss allocable to common stockholders $ (14,526,000) $ (29,653,000)
Weighted average shares outstanding (in shares) | shares 27,597,434 1,942,905
Basic and diluted net loss per common share (in dollars per share) | $ / shares $ (0.53) $ (15.26)
Net loss allocable to common stockholders $ (14,526,000) $ (29,653,000)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities not included in computation of diluted net income (loss) per common share (in shares) | shares 6,123,108 4,374,890
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of stock based compensation plans | Plan 2  
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Total stock-based compensation expense $ 4,368,000 $ 1,305,000
Tax benefit 0 0
Stock-based compensation expense, net of tax $ 4,368,000 1,305,000
Gene Therapy [Member]    
Licensed Technology [Abstract]    
Number of patent family | License 1  
Period of amortization of license 20 years  
Plasma-based Therapeutics [Member]    
Licensed Technology [Abstract]    
License fee $ 1,000,000  
License fee payable $ 4,000,000  
Common stock shares in lieu of cash (in shares) | shares 1,096,151  
Period of amortization of license 11 years  
Regulatory approval milestone payment (in shares) | shares 513,375  
Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated useful lives of property and equipment 3 years  
Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated useful lives of property and equipment 5 years  
Research and Development [Member]    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Total stock-based compensation expense $ 773,000 104,000
General and Administrative [Member]    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Total stock-based compensation expense 3,595,000 1,201,000
Operating Expense [Member]    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Total stock-based compensation expense $ 4,368,000 $ 1,305,000
Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities not included in computation of diluted net income (loss) per common share (in shares) | shares 3,799,024 4,164,756
Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities not included in computation of diluted net income (loss) per common share (in shares) | shares 2,324,084 210,134